Research
Evidence-based research
A Verdict Score is a judgement, and a judgement is worth exactly as much as what sits under it. This is what sits under ours: 27 guides carrying 50 distinct primary sources — 28 peer-reviewed studies plus FDA labelling and the regulatory record — alongside the pricing research behind all 509 provider rulings. Medical and mechanism claims here are cited to a primary source or they are not made. How the six factors are weighted against each other is set out in our published methodology.
27
research guides
50
distinct primary sources
28
peer-reviewed studies
The medicine
What the molecules do, what the pivotal trials actually showed, and what separates an FDA-approved product from a compounded one. Every efficacy and regulatory claim in this group is cited to a primary source.
Semaglutide vs Tirzepatide: Which Is Right for You?
Tirzepatide wins on raw weight loss in the trials; semaglutide is the longer-established, often cheaper option. Here is how to decide between them.
5 cited sources · updated 2026-07-24
Compounded vs Brand-Name GLP-1: Which Should You Choose?
Brand-name GLP-1 is FDA-approved and consistent; compounded is cheaper and more available but not FDA-approved. Here is how to decide honestly.
5 cited sources · updated 2026-08-07
Is Compounded Semaglutide Legit and Safe?
Compounded semaglutide is legal but not FDA-approved. Safety hinges on the pharmacy. Here is how to tell a legitimate program from a risky one.
3 cited sources · updated 2026-07-24
The market, and what it costs
What a month of compounded GLP-1 really costs across the providers we track, and how the regulatory ground under compounded supply has shifted underneath those prices.
What Compounded GLP-1 Costs Per Month
Compounded semaglutide runs roughly $93–$249/mo and tirzepatide about $125–$399/mo across the providers we track. Here is how to read the pricing.
1 cited source · updated 2026-08-07
What the End of GLP-1 Compounding Means for You
The FDA shortage that made compounded semaglutide and tirzepatide widely available is over. Here is who can still get compounded GLP-1 and who must switch.
7 cited sources · updated 2026-07-24
Dispatches: providers we screened but do not rank
Seven telehealth sellers screened together in August 2026. None is a partner, none carries a commercial link, and none sits on our scored board. Each dispatch records the price ladder as published, the terms sitting underneath it, and what could not be verified — including two providers we would tell most readers to walk away from.
The Edit Review: $209 Semaglutide, $309 Tirzepatide
The Edit prices semaglutide at $209 and tirzepatide at $309 month-to-month, and every prepay figure divides correctly. Our August 2026 ruling.
3 cited sources · updated 2026-08-07
Trellis Vitality Review: $150 Semaglutide
Trellis publishes the best-formed GLP-1 price table of the seven providers we screened in August 2026 — and no price ladder at all for anything else.
4 cited sources · updated 2026-08-07
Auren Rx Review: The Price Is $199, Not $169
Auren Rx publishes a subscribe rung and a no-commitment rung for every product it sells. Three things on the page will mislead you about which is which.
2 cited sources · updated 2026-08-07
Pepti Review: $99 Semaglutide, One Open Question
Pepti lists $99 semaglutide flat at every dose. Its own production data carries a $299-$449 ladder we could not reconcile. The August 2026 ruling.
5 cited sources · updated 2026-08-07
Vyvron Review: 13 Charges a Year, Not 12
Vyvron prints its prices with a slash-mo but bills every four weeks, and its tirzepatide cannot be bought monthly at all. The August 2026 ruling.
3 cited sources · updated 2026-08-07
Rehydra+ Review: Six Months, No Way Out
Rehydra+ advertises GLP-1 from $119 a month. Every membership is six months and non-cancelable, so the real minimum purchase is $714 to $2,514.
3 cited sources · updated 2026-08-07
Lighter You Review: The $99 That Buys Nothing
Lighter You advertises "start for just $99". Its cheapest programme is $145, there is no $99 tier, and no price on the site can be checked without an account.
2 cited sources · updated 2026-08-07
How we judge a provider
The rubric itself, and the checklist a reader can run without us. These two explain what the Verdict Score measures and why those six things rather than another six.
How We Grade GLP-1 Providers: The Verdict Score Explained
The Verdict Score rates every GLP-1 provider out of 100 on six weighted factors — the same rubric for every provider, and the score is never sold.
3 cited sources · updated 2026-07-24
How to Choose a GLP-1 Telehealth Provider
A decisive 8-point checklist for picking a GLP-1 telehealth provider: the molecule, honest pricing, real prescribers, verification, and a clean exit.
3 cited sources · updated 2026-08-07
Also in the library
Do GLP-1 Weight-Loss Patches Actually Work?
Semaglutide and tirzepatide are peptides roughly 8–10x too large to cross intact skin. Here is the pharmacology behind why a GLP-1 patch cannot work.
4 cited sources · updated 2026-08-03
GLP-1s and Sleep Apnea: What Zepbound's OSA Approval Actually Means
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Here is the SURMOUNT-OSA trial data and what it means for you.
5 cited sources · updated 2026-08-03
GLP-1 Drug Interactions: What Actually Interacts With Semaglutide and Tirzepatide
Semaglutide and tirzepatide slow digestion, which is the mechanism behind their real drug interactions — birth control pills, insulin, and narrow-window drugs.
4 cited sources · updated 2026-08-03
The GLP-1 Thyroid Cancer Boxed Warning, Explained
Wegovy and Zepbound carry a boxed warning for thyroid C-cell tumors, based on rodent studies. Here is what it says, who it excludes, and what human data show.
4 cited sources · updated 2026-08-03
GLP-1s, Pregnancy, and Breastfeeding: What the Label Actually Says
GLP-1s should be stopped before a planned pregnancy, but the breastfeeding guidance is not one-size-fits-all — it depends on tablet vs. injection. Here is why.
4 cited sources · updated 2026-08-03
Does Semaglutide or Tirzepatide Cause Hair Loss?
Two large cohort studies now show a real, measurable increase in new-onset hair loss on GLP-1s. Here is the data, the likely mechanism, and what helps.
2 cited sources · updated 2026-08-03
GLP-1s, Your Gallbladder, and Your Pancreas: What the Trials Actually Show
Rapid weight loss and GLP-1s both raise gallstone risk, and pancreatitis is a labeled warning on both drugs. Here are the actual trial rates and warning signs.
3 cited sources · updated 2026-08-03
Compounded Semaglutide Dosing Errors: What the FDA Safety Alert Says
The FDA has received reports of hospitalizations from dosing errors with compounded semaglutide vials. Here is exactly what goes wrong, and how to avoid it.
2 cited sources · updated 2026-08-03
Who Qualifies for a GLP-1 — and Who Shouldn't Take One
The FDA label sets specific BMI and comorbidity criteria for Wegovy and Zepbound, plus hard exclusions. Here is exactly who qualifies and who is ruled out.
4 cited sources · updated 2026-08-03
“Ozempic Face”: What Causes Facial Fat Loss on a GLP-1 (and What Helps)
“Ozempic face” is real and now has a dermatologic-surgery literature behind it. Here is why it happens, who is most affected, and what actually helps.
2 cited sources · updated 2026-08-03
Why GLP-1 Weight Loss Stalls, and What Actually Works
A weight-loss plateau on semaglutide or tirzepatide is expected, not a sign of failure. Here is the trial data on why it happens and what to check first.
3 cited sources · updated 2026-08-03
How Much Muscle Do You Lose on Semaglutide or Tirzepatide?
Body-composition substudies show roughly a quarter to a third of GLP-1 weight loss is lean mass, not fat. Here is the actual data and how to protect it.
3 cited sources · updated 2026-08-03
GLP-1s and Vision Loss: What the NAION Studies Actually Show
A rare form of vision loss called NAION has an emerging association with semaglutide in real-world data. Here is what the studies found and who is at risk.
2 cited sources · updated 2026-08-03
Where the research meets the rulings
The evidence above decides what a good programme looks like; the 509 provider verdicts decide which ones clear the bar. Pricing is the half that has to be re-read rather than cited: figures come from each provider's own live pages, they carry the condition attached to them, and when we read one back against the provider's site and find it wrong we correct it in public. Who writes this, and how corrections are handled, is in our editorial policy.